PHARMACOKINETICS OF MITOXANTRONE IN PLASMA AND LEUKEMIC-CELLS DURING TREATMENT OF PATIENTS WITH ACUTE NONLYMPHOCYTIC LEUKEMIA

被引：10

作者：

GRUBER, A

LILIEMARK, J

TIDEFELT, U

KNOCHENHAUER, E

ARESTROM, I

SUNDMANENGBERG, B

BJORKHOLM, M

PAUL, C

PETERSON, C

机构：

[1] Division of Hematology and Immunology, Department of Medicine, Stockholm

[2] Department of Clinical Pharmacology, Karolinska Hospital, Stockholm

[3] Division of Clinical Hematology and Oncology, Department of Medicine, Huddinge Hospital, Huddinge

来源：

LEUKEMIA & LYMPHOMA | 1992年 / 6卷 / 06期

关键词：

MITOXANTRONE; PHARMACOKINETICS; LEUKEMIC CELLS; ACUTE NONLYMPHOCYTIC LEUKEMIA;

D O I：

10.3109/10428199209053588

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The pharmacokinetics of mitoxantrone was studied in the plasma and peripheral leukemic cells in 14 patients receiving induction treatment for acute non-lymphocytic leukemia. The disappearance of mitoxantrone from plasma was biphasic with a mean distribution half life of 10.4 minutes and a mean elimination half life of 17.1 hours. At the end of the infusion, the mean mitoxantrone concentration in leukemic cells was 9.6 times (range 2.1-22.7) higher than in plasma and remained relatively stable in the cells until the next infusion following 24 hours after the first. The area under the concentration-time curve (AUC0-20h) in leukemic cells was 23-191 times larger than the AUC0-α in plasma. In the individual patient there was no correlation between the AUC in leukemic cells and AUC in plasma. Since mitoxantrone acts intracellularly, concentrations in the leukemic cells might predict the antileukemic effect better than plasma concentrations. © 1992 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

引用

页码：493 / 496

页数：4

共 15 条

[1]

Ho A., Seither E., Ma D., Prentice H., Mitoxantrone-induced toxicity and DNA strand breaks in leukaemic cells, Br. J. Haematol., 65, pp. 51-55, (1987)

[2]

Alberts D., Peng Y., Bowden G., Mackel C., Dalton W., Mechanism of action and pharmacokinetics of Novantrone in intravenous and intraperitoneal therapy, pp. 21-24, (1985)

[3]

Ehninger G., Schuler U., Proksch B., Zeller K., Blanz J., Pharmacokinetics and metabolism of mitoxantrone, a review, Clin. Pharmacokinet., 18, pp. 365-380, (1990)

[4]

Savaraj N., Lu K., Manuel V., Loo T., Pharmacology of mitoxantrone in cancer patients, Cancer Chemother. Pharmacol, 8, pp. 113-117, (1982)

[5]

Stewart D., Green R., Mikhael N., Montpetit V., Thibault M., Maroun J., Human autopsy tissue concentrations of mitoxantrone, Cancer Treat. Rep., 70, pp. 1255-1261, (1986)

[6]

Bjorkholm M., Bjornsdottir J., Stenke L., Grimfors G., Mitoxantrone, etoposide and cytarabine in the treatment of acute nonlymphocytic leukemia, Oncology, 47, pp. 112-114, (1990)

[7]

Larson R., Daly K., Choi K., Han D., Sinkule J., A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia, J. Clin. Oncol, 5, pp. 391-397, (1987)

[8]

Dunne A., JANA: A new iterative polyexponential curve stripping program, Comput. Methods Programs Biomed., 20, pp. 269-275, (1985)

[9]

Eksborg S., Strandler H., Edsmyr F., Naslund I., Tahvanainen P., Pharmacokinetic study of iv infusions of adriamycin, Eur. J. Clin. Pharmacol., 28, pp. 205-212, (1985)

[10]

Tidefelt U., Sundman-Engberg B., Paul C., Comparison of the intracellular pharmacokinetics of doxorubicin and 4′-epi-doxorubicin in patients with acute leukemia, Cancer Chemother. Pharmacol, 24, pp. 225-229, (1989)

← 1 2 →